Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can immune profiling unlock the hidden stages of tuberculosis?

NCT ID NCT07735754

Knowledge-focused Sponsor: Irene Latorre Rueda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could predict infection risk, disease progression, and treatment success. The goal is to develop innovative tools for managing all phases of TB.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better tools for detecting and managing tuberculosis at all stages, potentially reducing transmission and improving treatment outcomes.
What could go wrong
This is an observational study, so it will not test a new treatment. The findings may not directly translate into clinical practice without further research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 940 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The participants will be recruited in 4 different hospitals located in Moldova (Chiril Draganiuc Institute, IPCD), Romania (Marius Nasta Institute, IPMN), Nigeria (Bingham University, BHU) and Spain (Serveis Clínics, SSCC).

Ages

5 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 5 and 65 years * Willing and able to provide informed consent (or legal guardian consent) \*GROUP 1: Active pulmonary TB\* * Bacteriologically confirmed TB * Pulmonary TB * Anti-TB treatment ≤ 14 days \*GROUP 2: Close contacts of active pulmonary TB\* * Close contact with confirmed pulmonary TB case * Exposure ≥6 hours/day for ≥5 days/week * Positive TST and/or IGRA * NOT receiving TB preventive therapy \*GROUP 3: Other respiratory diseases (non-TB)\* * Diagnosis of ARI (Acute Respiratory Infection) and/or sarcoidosis and/or lung cancer * Clinical/radiological findings consistent with non-TB disease * NO clinical suspicion compatible with active TB \*GROUP 4: Healthy uninfected controls\* * No symptoms suggestive of active TB * Not known prior exposure to active TB * Negative TST and/or IGRA Exclusion Criteria: * Known or suspected immunodeficiency (including HIV or immunosuppressive therapy) * Known or suspected pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer pulmonary tuberculosis respiratory tract infectious disorder sarcoidosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberculosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.